Artikel mit Open-Access-Mandaten - Robert Haddad, M.D.Weitere Informationen
Nicht verfügbar: 7
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised …
NY Lee, RL Ferris, A Psyrri, RI Haddad, M Tahara, J Bourhis, K Harrington, ...
The Lancet Oncology 22 (4), 450-462, 2021
Mandate: Cancer Research UK, National Institute for Health Research, UK
Thyroid carcinoma, version 2.2014
RM Tuttle, RI Haddad, DW Ball, D Byrd, P Dickson, QY Duh, H Ehya, ...
Journal of the National Comprehensive Cancer Network 12 (12), 1671-1680, 2014
Mandate: US National Institutes of Health
Defining an inflamed tumor immunophenotype in recurrent, metastatic squamous cell carcinoma of the head and neck
GJ Hanna, H Liu, RE Jones, AF Bacay, PH Lizotte, EV Ivanova, ...
Oral oncology 67, 61-69, 2017
Mandate: Damon Runyon Cancer Research Foundation
A phase II trial of all-trans retinoic acid (ATRA) in advanced adenoid cystic carcinoma
GJ Hanna, A ONeill, JM Cutler, M Flynn, T Vijaykumar, JR Clark, LJ Wirth, ...
Oral oncology 119, 105366, 2021
Mandate: US National Institutes of Health
Salivary and serum HPV antibody levels before and after definitive treatment in patients with oropharyngeal squamous cell carcinoma
GJ Hanna, V Sridharan, DN Margalit, SK La Follette, NG Chau, ...
Cancer Biomarkers 19 (2), 129-136, 2017
Mandate: US National Institutes of Health
Long-term outcomes and clinicogenomic correlates in recurrent, metastatic adenoid cystic carcinoma
GJ Hanna, JE Bae, JH Lorch, JD Schoenfeld, DN Margalit, RB Tishler, ...
Oral Oncology 106, 104690, 2020
Mandate: V Foundation, USA
Randomized phase II trial of cixutumumab alone or with cetuximab for refractory recurrent/metastatic head and neck squamous cell carcinoma
R Ferrarotto, WN William Jr, JE Tseng, S Marur, DM Shin, B Murphy, ...
Oral Oncology 82, 83-90, 2018
Mandate: US National Institutes of Health
Verfügbar: 72
Nivolumab for recurrent squamous-cell carcinoma of the head and neck
RL Ferris, G Blumenschein Jr, J Fayette, J Guigay, AD Colevas, L Licitra, ...
New England Journal of Medicine 375 (19), 1856-1867, 2016
Mandate: US National Institutes of Health, National Institute for Health Research, UK
Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE …
LQM Chow, R Haddad, S Gupta, A Mahipal, R Mehra, M Tahara, R Berger, ...
Journal of Clinical Oncology 34 (32), 3838-3845, 2016
Mandate: US National Institutes of Health
Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by …
RL Ferris, G Blumenschein Jr, J Fayette, J Guigay, AD Colevas, L Licitra, ...
Oral oncology 81, 45-51, 2018
Mandate: US National Institutes of Health, National Institute for Health Research, UK
Head and neck cancers, version 2.2014
DG Pfister, S Spencer, DM Brizel, B Burtness, PM Busse, JJ Caudell, ...
Journal of the National Comprehensive Cancer Network 12 (10), 1454-1487, 2014
Mandate: US National Institutes of Health
Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial
MR Posner, JH Lorch, O Goloubeva, M Tan, LM Schumaker, NJ Sarlis, ...
Annals of oncology 22 (5), 1071-1077, 2011
Mandate: US National Institutes of Health
Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors
D Miao, CA Margolis, NI Vokes, D Liu, A Taylor-Weiner, SM Wankowicz, ...
Nature genetics 50 (9), 1271-1281, 2018
Mandate: US National Institutes of Health, Howard Hughes Medical Institute
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results …
JH Lorch, O Goloubeva, RI Haddad, K Cullen, N Sarlis, R Tishler, M Tan, ...
The lancet oncology 12 (2), 153-159, 2011
Mandate: US National Institutes of Health
Characterization of HPV and host genome interactions in primary head and neck cancers
M Parfenov, CS Pedamallu, N Gehlenborg, SS Freeman, L Danilova, ...
Proceedings of the National Academy of Sciences 111 (43), 15544-15549, 2014
Mandate: US National Institutes of Health
Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related …
KJ Harrington, RL Ferris, G Blumenschein, AD Colevas, J Fayette, ...
The Lancet Oncology 18 (8), 1104-1115, 2017
Mandate: US National Institutes of Health, National Institute for Health Research, UK
Response and acquired resistance to everolimus in anaplastic thyroid cancer
N Wagle, BC Grabiner, EM Van Allen, A Amin-Mansour, A Taylor-Weiner, ...
New England Journal of Medicine 371 (15), 1426-1433, 2014
Mandate: US National Institutes of Health, Howard Hughes Medical Institute
Racial survival disparity in head and neck cancer results from low prevalence of human papillomavirus infection in black oropharyngeal cancer patients
K Settle, MR Posner, LM Schumaker, M Tan, M Suntharalingam, ...
Cancer prevention research 2 (9), 776-781, 2009
Mandate: US National Institutes of Health
Genomic analysis of metastatic cutaneous squamous cell carcinoma
YY Li, GJ Hanna, AC Laga, RI Haddad, JH Lorch, PS Hammerman
Clinical cancer research 21 (6), 1447-1456, 2015
Mandate: US National Institutes of Health
Chemotherapy in combination with radiotherapy for definitive-intent treatment of stage II-IVA nasopharyngeal carcinoma: CSCO and ASCO guideline
YP Chen, N Ismaila, MLK Chua, AD Colevas, R Haddad, SH Huang, ...
Journal of Clinical Oncology 39 (7), 840-859, 2021
Mandate: US National Institutes of Health
Angaben zur Publikation und Finanzierung werden automatisch von einem Computerprogramm ermittelt